The healthcare sector, as measured by the XLV ETF, moved lower by 1.33% in the current session without a clear, negative news catalyst specific to the US market. This decline comes despite positive clinical trial news from major components like Eli Lilly and Merck, and a mixed-to-positive broader market. The most significant negative healthcare news of the day originated from India, where regulatory comments on drug pricing caused a sharp sell-off in local healthcare stocks. This may be creating a negative sentiment spillover for the sector globally.